L-Ascorbic acid (L-Ascorbate)，一种电子供体，是一种内源性抗氧化剂。L-Ascorbic acid 选择性抑制 Cav3.2 通道 (Cav3.2 channels)，IC50为 6.5 μM。L-Ascorbic acid 还是一种胶原沉积促进剂和弹性生成抑制剂。L-Ascorbic acid通过产生活性氧 (ROS) 和选择性损伤癌细胞表现出抗癌作用。
| 生物活性 | L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectivelyCav3.2 channelswith anIC50of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor[1][2][3]. L-Ascorbic acid exhibits anti-cancer effects through the generation ofreactive oxygen species(ROS) and selective damage tocancercells[4]. |
| IC50& Target | Microbial Metabolite | Human Endogenous Metabolite |
|
体外研究
(In Vitro) | The anti-cancer effects of L-Ascorbic acid are determined by sodium-dependent vitamin C transporter 2 (SVCT-2), a transporter of L-ascorbic acid. L-Ascorbic acid (0.1 μM-2 mM) exhibits anti-cancer effects according to SVCT-2 expression and L-ascorbic acid uptake. Human colorectal cancer cell lines displays differential responses to L-ascorbic acid, primarily depending on the expression level of SVCT-2[4].
Cell Viability Assay[4] | Cell Line: | High SVCT-2 expressing cell lines Sw620, Sw480, LoVo, SNU-C4; Low SVCT-2 expressing cell lines HCT15, HCT116, DLD-1, CoLo-205 | | Concentration: | 0, 0.1 μM, 1 μM, 10 μM, 0.1 mM, 0.5 mM, 1 mM, and 2 mM | | Incubation Time: | 24 hours | | Result: | Some high SVCT-2 expressing cancer cells demonstrated a dramatic cell-autonomous inhibitory effect of L-ascorbic acid.
Low SVCT-2 expressing cell lines showed biphasic responses to L-ascorbic acid. |
Western Blot Analysis[4] | Cell Line: | Sw620, Sw480, LoVo, SNU-C4, HCT15, HCT116, DLD-1, CoLo-205 cell lines | | Concentration: | 1 mM | | Incubation Time: | | | Result: | The cell lines showed different levels of SVCT-2 expression in western blot analyses: Sw620, Sw480, and Lovo expressed high levels of SVCT-2 whereas HCT116, HCT15, and DLD-1 expressed low levels. |
|
体内研究
(In Vivo) | L-Ascorbic acid/Tolbutamide produces hypoglycaemic activity in a dose dependant manner in normal (60 mg/kg) and diabetic (40 mg/kg) condition. In the presence of L-ascorbic acid, Tolbuatmide (20 mg/kg) produces early onset of action and maintained for longer period compared to Tolbutamide matching control[5].
| Animal Model: | Normal rats:Albino rats of either sex weighing between 125-175 g[5] | | Dosage: | Group I received L-ascorbic acid 60 mg/kg, Group II received Tolbutamide 20 mg/kg and Group III was given L-ascorbic acid (60 mg/kg) prior to the administration of tolbutamide 20 mg/kg | | Administration: | Administered orally | | Result: | L-ascorbic acid at the dose of 60 mg/kg produced 50.91% blood glucose reduction at 0.5 h and 20 mg/kg body weight of Tolbutamide produced 33% at 4 h as peak effects. In the presence of L-ascorbic acid (60 mg/kg), the action of Tolbutamide was early in onset and maintained for 6 h. |
| Animal Model: | Diabetic rats:Albino rats of either sex weighing between 125 to 175 g were fasted overnight before injection with Alloxan[5] | | Dosage: | Group I received L-ascorbic acid 40 mg/kg and Group II received Tolbutamide 20 mg/kg while Group III was given L-ascorbic acid 40 mg/kg prior to Tolbutamide administration (20 mg/kg). | | Administration: | Oral administration | | Result: | L-ascorbic acid (40 mg/kg alone) produced 42.53% blood glucose reduction at 1.5 h and Tolbutamide 20 mg/kg produced 45.09 at 4 h. Administration of L-ascorbic acid 40 mg/kg body weight prior to Tolbutamide produced antidiabetic activity at 0.5 h and was maintained for 6 h. |
|
| Clinical Trial | |
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 结构分类 | |
| 来源 | - Plants
- Moringaceae
- Moringa oleiferaLam.
|
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| 溶解性数据 | In Vitro: DMSO : 100 mg/mL(567.79 mM;Need ultrasonic) H2O : ≥ 100 mg/mL(567.79 mM) *"≥" means soluble, but saturation unknown. 配制储备液 | 1 mM | 5.6779 mL | 28.3897 mL | 56.7795 mL | | 5 mM | 1.1356 mL | 5.6779 mL | 11.3559 mL | | 10 mM | 0.5678 mL | 2.8390 mL | 5.6779 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (protect from light)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： PBS Solubility: 100 mg/mL (567.79 mM); Clear solution; Need ultrasonic and warming and heat to 60℃
*以上所有助溶剂都可在本网站选购。 |
m.cnreagent.com